glp -1 agonist GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders What You Should Know Before

A recent study, published in the Journal of Pharmacy and Pharmacology Research, sugges

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

GoodRx reports that while satisfaction with GLP-1s for weight loss is high, costs and access issues significantly impact patient experiences.

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020

The primary outcome was change in HbA1c from baseline

Mounjaro is dual-acting, while Ozempic affects one gut hormone.